LOXL2 and lung carcinoma: Therefore, mechanistically validating LAIR1 and SHP-1 as additional therapeutic targets in combination with PD-1/PD-L1 blockade is vital to circumvent the need for early LOXL2 inhibition and to allow treatment of lung cancer patients with late-stage disease.